Clinical Trial

Phase I/II Study of SCTB39-1 in Advanced Solid Tumours

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39-1 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-25.
Trial Details
NCT Number NCT07050641
Lead Sponsor Sinocelltech Ltd.
Conditions Advanced Malignant Solid Tumor
Enrollment 110 participants
Start Date 2025-06-23
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-04